Domů › Mnohočetný myelom › Colorado › Denver
Klinické studie Mnohočetný myelom v Denver, CO
27 studií pro Mnohočetný myelom hledá účastníky v lokalitách v Denver a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Probíhá náborFáze 2
- Colorado Blood Cancer Institute, Denver
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Probíhá náborFáze 1
- Colorado Blood Cancer Institute /ID# 280275, Denver
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Probíhá náborFáze 3
- Research Site, Denver
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Probíhá náborFáze 1
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 3
- Colorado Blood Cancer Institute, Denver
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Probíhá náborFáze 2
- Colorado Blood Cancer Institute, Denver
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Probíhá náborFáze 1
- Research Site, Denver
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Probíhá náborFáze 1
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 3
- Colorado Blood Cancer Institute, Denver
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Probíhá náborFáze 2/3
- Colorado Blood Cancer Institute /ID# 279080, Denver
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Probíhá náborFáze 3
- CBCI, Colorado Blood Cancer Institute, Denver
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 1
- Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 2
- Colorado Blood Cancer Institute, Denver
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Probíhá náborFáze 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 1/2
- Research Site, Denver
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Probíhá náborFáze 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Probíhá náborFáze 1/2
- Research Site, Denver
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Probíhá náborFáze 3
- Research Site, Denver
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Probíhá náborFáze 1/2
- Colorado Blood Cancer Institute /ID# 273129, Denver
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Probíhá náborFáze 2
- Colorado Blood Cancer Institute, Denver
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Probíhá náborFáze 3
- Colorado Blood Cancer Institute, Denver
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Probíhá náborFáze 2
- Colorado Blood Cancer Institute, Denver
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Probíhá náborFáze 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 1
- Colorado Blood Cancer Institute /ID# 273751, Denver
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Probíhá náborFáze 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Probíhá náborFáze 1/2
- Colorado Blood Cancer Institute, Denver
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Probíhá náborFáze 1
- Colorado Blood Cancer Institute, Denver
Studie Mnohočetný myelom v jiných městech
- New York City, NY60 studií
- Boston, MA42 studií
- Atlanta, GA41 studií
- Houston, TX38 studií
- Durham, NC37 studií
- Nashville, TN32 studií
- Rochester, MN24 studií
- St. Louis, MO24 studií
- Columbus, OH24 studií
- Baldwin Park, CA23 studií
- Chicago, IL22 studií
- Seattle, WA22 studií
Další studie v Denver
- Metastatický karcinom29 studií
- Rakovina prsu28 studií
- Nemalobuněčný plicní karcinom27 studií
- Kolorektální karcinom23 studií
- Rakovina prostaty19 studií
- Melanom19 studií
- Rakovina (všechny typy)18 studií
- Rakovina vaječníků16 studií
- Rakovina plic16 studií
- Rakovina endometria15 studií
- Non-Hodgkinův lymfom14 studií
- Rakovina slinivky břišní13 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.